November 15, 2017
Incyte is testing to see whether Ruxolitinib is beneficial for people with Essential Thrombocythemia, who are resistance or intolerant to Hydroxyurea. The primary endpoint of this study is platelet and White Blood Cell (WBC) control over 1 year of follow-up. Key secondary endpoints include safety and tolerability as well as complete remission (CR) or partial remission (PR). For more information about the study, please visit https://clinicaltrials.gov/ct2/show/NCT03123588.
Ruxolitinib was approved (marketing name of Jakafi) for Myelofibrosis in 2011, and later for Polycythemia Vera patients who are resistant or intolerant to Hydroxyurea in 2014. Jakafi remains the only FDA approved drug for any of the Myeloproliferative Neoplasms.